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Introduction
The European Seminars in Respiratory Medicine has represented an
outstanding series updating new science in respiratory disease from the
1990’s up to the early beginning of this 21st century [1,2]. Its aim is to
update issues and current science, focusing on the multidisciplinary ap-
proach to patients with respiratory disease. As such, it represents a
unique opportunity for specialists in Respiratory Medicine involved in
Basic and Clinical Research to discuss topical and debated problems in
medical care, at a top level forum guided by an expert panel of authors. 
The structure of the seminar is based on the following pillars:
• Attendance at the Seminars is strictly limited: selection of partici-
pants is based, in order of priority, on scientific curriculum, age
(younger specialists are privileged), and early receipt of the applica-
tion form. 
• Each topic is allotted considerable time for presentation and discus-
sion. The first section is devoted to a series of presentations (with
adequate time allocated for discussion) by an expert panel of re-
searchers and clinicians. In the second section involves discussions
of controversial issues, in a smaller audience format encouraging in-
teraction between the panel and audience.
• “Meet the expert” seminars discuss topical subjects in more depth,
utilizing an interactive tutorial.
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Unlike prevalence, the incidence of a disease measures the risk of
developing new disease within a specified period of time. Annual inci-
dence is calculated as the number of new cases occurring in 12 months
divided by the population who was diseases-free at the beginning of the
period. Incidence can be hard to measure as it involves knowing sub-
jects who are disease-free at the beginning of the period; a prospective
study design is needed [3,4].
Prevalence and incidence are interrelated. In particular, the preva-
lence depends on disease incidence and duration. A high prevalence
may be due to a high incidence, and/or a long duration of the dis-
ease; an increase in prevalence over time may be due to an increase
in incidence, or a longer duration of the disease (i.e., longer sur-
vival) [4,5].
Definition of COPD matters in prevalence studies
Different criteria can be used to define COPD, and this methodolog-
ical aspect is relevant to epidemiology, when data from different
studies and populations have to be compared or pooled together [6,7].
For spirometry-defined COPD, the disease prevalence in a general pop-
ulation depends on the threshold used for determining airflow limita-
tion [6]. A definition based on a fixed value of FEV1/FVC (<0.70) over-
estimates COPD in the elderly, and under-underestimates it in the
younger people. To define COPD as a FEV1/FVC ratio below the lower
limit of normal (LLN) takes into account the age-related changes in
lung function [8,9].
Prevalence of COPD
COPD global prevalence
A recent review estimates COPD prevalence for the years 1990 and
2010 across six world regions, based on the best available evidence in
publicly accessible scientific databases [10]. In 123 selected studies of
52 countries, the global prevalence of spirometry-defined COPD (93%
defined by FEV1/FVC <0.70) in subjects over 30 years of age was 11.3%
in the year 2010. The highest prevalence was found in the Americas re-
gion, followed by Eastern Mediterranean and European regions,
whereas the lowest in the South-East Asian region. The prevalence was
higher in men (14.3%) than in women (7.6%), in high than in low-
middle income countries (12.0 vs 10.6), in urban than in rural areas
(13.2 vs 10.2) [10]. About 227 million COPD cases were estimated in
1990 (global prevalence 10.7%); the number of estimated case in-
creased to 384 million in 2010. This 68.9% increase is mainly driven by
global demographic changes over the 20 years period; however, other
factors underline the current trend. The lowest increase in total
number of COPD cases in the European region may reflect reduction in
prevalence of smoking in Europe; gender related differences among the
different regions are evident [10]. 
Prospective studies conducted in elderly population in Europe
[11,12] showed that the age-specific incidence of COPD increased
with age until 80 years. The incidence increased by age also in never
smoking older subjects [11]: the detection of new cases in never
smokers indicates that additional factors may independently contribute
to COPD development, mainly environmental conditions (outdoor and
indoor pollution, climate changes).
Prevalence of COPD from Italian population-based
studies
The Pulmonary Environmental Epidemiology Unit of the Institute of
Clinical Physiology (EPAP-IFC) of the National Research Council
(CNR) started to carry out epidemiological surveys on general popula-
tion samples in Italy in the ‘80s. In particular, the main objective was to
The Seminar is accredited to provide continuing medical education
(CME) for Italian physicians, with approval of up to 100 participants,
providing 10 CME credits to professionals in the following specialties:
Allergology and Immunology, Anesthesiology. Cardiology, Geriatrics,
General Practice, Internal Medicine, Pulmonology, Radiology, Rehabili-
tation, Rheumatology, and Thoracic Surgery.
The recent epidemiologic trend, placing chronic obstructive pul-
monary disease (COPD) as the third-leading cause of death worldwide,
underscores the huge burden placed on society by this disease. This in-
cludes disability, higher mortality risk, direct health service costs (in-
cluding pharmaceutical, inpatient, outpatient, and supplemental
oxygen costs), as well as prominent indirect costs (including lost pro-
duction and burden on families) [3]. The prevalence COPD, its social
and economic burdens, and the complexity of the problems present in
the patient with advanced disease necessitate a new and more struc-
tured approach to the long term management of this disease.
The objectives of this Seminar on “The Long Term Integrated Care of
COPD Patients” held in Stresa, Italy, from 16-17 June, 2016, were: 
• Description of the concepts of integrated care and chronic disease
management.
• Discussion of specific components of disease management as they
may apply to the COPD patient.
• Provision of several innovative examples of COPD disease manage-
ment programs originating from different health care systems.
The scientific contents of this seminar focused on the optimal care
of the COPD patient. Optimizing care for the complex COPD patient re-
quires: i) An individualized, patient-centered approach, recognizing
and treating all aspects of the respiratory disease, its systemic effects
and common co-morbidities; and ii) integrating medical care among
health care professionals and across the health care sector. Optimal in-
tegration of medical care for COPD is still in its infancy, and its imple-
mentation will undoubtedly represent a paradigm shift in our thinking.
In particular, the scientific program of this Seminar described in detail
the specific components of disease management that apply to the
COPD patient, providing innovative examples programs originating
from different health care systems, providing an opportunity to com-
pare approaches implemented in different countries.
Prevalence of COPD
Key points
• A high and growing prevalence of COPD, both globally and re-
gionally, with substantial variation in trends between dif-
ferent regions is observed
• The prevalence of respiratory symptoms/diseases is still in-
creasing in the Italian general population
• Occupational exposure and living in an urban area are re-
lated to asthmatic and/or allergic symptoms/diagnosis 
• Smoking habits, occupational exposure and living in an urban
area are related to bronchitic symptoms
Prevalence and incidence
The prevalence of a disease measures the number of cases of the dis-
ease in a population at a given time, even though the process of the data
collection may take place over days, weeks, or years. It is calculated as
the number of people with the disease divided by the total population at
the time of data collection, usually expressed as a percentage [3].The
prevalence rate has to be collected through cross-sectional studies: it
provides a static measure; it estimates the burden of the disease; and it
can be useful for public health research and decision-making [3-5]. 
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study the natural history of COPD in two general population samples
living in Northern (Po river Delta area - PD) and Central (Pisa urban
and suburban area - PI) Italy, in relation to risk factors such as smoking
and environmental pollution. 
Changes in prevalence of respiratory symptoms/diseases between
the first and the second cross-sectional surveys, in subjects living in
rural and urban area, were analyzed: the highest variations were
shown in PD subjects under 25 years, especially for wheeze (1st-2nd
survey prevalence: 6.0-17.0% in males, 4.0-12.0% in females), attacks
of wheeze (3.0-6.0% in males), dyspnea (2.0-6.0% in males, 3.0-
11.0% in females) and cough (5.0-10.0% in females), which in-
creased two to three fold. In PI, only wheeze in both sexes increased
(14.0-22.0% in males, 10.0-15.0% in females) [13]. A different pat-
tern between sexes was observed in subjects aged 25-64 years:
wheeze and dyspnea consistently increased in PD men (14.0-27.0%
and 13.0-17.0%, respectively), whilst cough (7.0-11.0% in PD and
11.0-15.0% in PI), phlegm (6.0-11.0% in PD and 7.0-10.0% in PI) and
wheeze (7.0-14.0% in PD and 13.0-19.0% in PI) increased in women
in both areas. Moreover, PI females showed a significant increase in
dyspnea (19.0-29.0%) [13]. Recent analyses on PI sample showed
that the adjusted prevalence rates of asthma attacks, allergic rhinitis
(AR) and COPD increased in a period of 25 years: current asthma at-
tacks (1st-3rd survey prevalence: 3.4-7.2%), AR symptoms/disease
(16.2-37.4%), usual phlegm (8.7-19.5%) and COPD (2.1-6.8%) more
than doubled from PI1 to PI3. Fewer increases were shown for usual
cough and airway obstruction (AO) (11.4-16.3%, 10.8-21.1%, respec-
tively) [14].
A generalized estimating equations (GEE) model showed significant
relationships between asthmatic and/or allergic symptoms/diagnosis
and occupational exposure: a 20% higher risk of asthma and attacks of
asthma and 40% higher risk of AR in subjects exposed to
fumes/gases/dusts at work, with respect to unexposed subjects. Living
in an urban area, with respect to living in a suburban one, was associ-
ated to a 20% higher risk of AR [14]. Smoking habits, occupational ex-
posures and living in an urban area were related to bronchitic symp-
toms/diagnosis. In particular, subjects exposed at work had a higher
risk of usual cough, usual phlegm and COPD with respect to unexposed
subjects (25%, 40% and 80% higher risk, respectively). Heavy smoking
habit (≥24 pack-years), with respect to non smoking, was associated
with a nearly 340% higher risk of bronchitic symptoms/diagnosis; a
nearly 170% higher risk was shown for AO. At last, living in an urban
area, with respect to living in a suburban one, was related to a higher
risk of usual phlegm (30%) and COPD (50%) [14].
These data confirm the increasing trend in asthmatic and allergic
diseases/symptoms found in other national and international studies
[15-17]. With regard to the COPD symptoms/diagnosis trend, re-
peated cross-sectional studies reported inconsistent results so far;
our study added new evidences about the COPD increase in the last
decades, confirming data from a Norwegian study that show an in-
creasing prevalence of spirometry-defined COPD (i.e. FEV1/FVC
<0.70) from 7% to 14% in nine years (15). Instead, Spanish and
Swedish studies reported a decreasing trend in the prevalence of
COPD over 10-15 years periods (from 9.1% to 4.5% and from 9.5% to
6.3%, respectively) [18].
Urban living is a risk factor for allergic rhinitis and COPD symp-
toms/diagnosis, confirming our previous findings obtained through a
geographic information system approach [19]; moreover, the current
data are in line with our previous study showing that urban living is
associated with higher bronchial hyper-responsiveness [20] and in
agreement with an American Thoracic Society statement high-
lighting the relationship between outdoor pollution and COPD devel-
opment [21].
An overview of COPD 
Key points
• 5-10% of adults aged over 40 years have COPD, with a higher
prevalence in men than women
• The key risk factor for chronic obstructive pulmonary disease
is tobacco smoke, but occupational exposures, pollution and
genetic factors play a role
• The most important symptoms of chronic obstructive pul-
monary disease are breathlessness on exertion and chronic
cough with or without phlegm, but fatigue, anorexia and
weight loss can arise as the disease progresses
• Treatment of COPD is multimodal, including smoking cessa-
tion, medical treatment with bronchodilators as well as in-
hibitors of inflammation, physical exercise and oxygen
therapy
COPD is characterized by persistent airflow limitation that is usually
progressive and associated with a chronic inflammatory response in
the airways and lungs to noxious particles or gases [22]. The per-
sistent airflow limitation results from a combination of diffuse small
airway disease and destruction of the lung parenchyma (emphysema)
[23]. Chronic bronchitis is defined clinically as the presence of a
chronic productive cough for 3 months during each of 2 consecutive
years (other causes of cough excluded). Emphysema is defined patho-
logically as an abnormal, permanent enlargement of the air spaces
distal to the terminal bronchioles, accompanied by destruction of their
walls and without obvious fibrosis [24].
COPD affects 32 million persons in the United States and is the third
leading cause of death in that country. The National Health Interview
Survey reports the prevalence of emphysema at 18 cases per 1000 per-
sons and chronic bronchitis at 34 cases per 1000 persons [25]. Overall,
5-10% of adults aged over 40 years in Europe have COPD, with a higher
prevalence in men than women. The mortality rate, age-standardized to
the European Standard Population, is about 18 per 100 000 inhabitants
per year [26]. COPD does occur in individuals who have never smoked
[27]. Although the role of air pollution in the etiology of COPD is un-
clear, its effect is small compared with that of cigarette smoking [28].
In developing countries, the use of biomass fuels with indoor cooking
and heating is a major contributor to the worldwide prevalence of
COPD. Long-term exposure to traffic-related air pollution may also be a
factor in COPD in patients with diabetes and asthma [29,30]. The
Dutch hypothesis postulates that individuals with nonspecific airway
hyperreactivity who smoke cigarettes have an accelerated decline in
lung function and, therefore, are at a particularly high risk of devel-
oping COPD. Nonspecific airway hyperreactivity is inversely related to
FEV1 predicts a more rapid decline in lung function. However, the po-
tential role of airway hyperresponsiveness as a risk factor in the devel-
opment of COPD in smokers is still unclear. Moreover, bronchial hy-
perreactivity may result from airway inflammation observed with the
development of smoking-related chronic bronchitis. This may con-
tribute to airway remodeling, leading to a fixed obstruction as is seen
in COPD. Alpha-1-antitrypsin (AAT) is a glycoprotein member of the
serine protease inhibitor family that is synthesized in the liver and is
secreted into the bloodstream. This 394-amino-acid, single-chain pro-
tein neutralizes neutrophil elastase in the lung interstitium, thereby
protecting it from elastolytic breakdown. Severe AAT deficiency predis-
poses to unopposed elastolysis, with the clinical sequela of early-onset
of panacinar emphysema. AAT deficiency is the only known major ge-
netic risk factor for developing COPD, accounting for somewhat less
pimeEDITRICE
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should be offered to all patients older than 65 years or to patients of any
age who have an FEV1 of less than 40% of predicted. The influenza vac-
cine should be given annually to all COPD patients.
Many patients with COPD are unable to enjoy life to the fullest be-
cause of shortness of breath, physical limitations, and inactivity. Pul-
monary rehabilitation encompasses an array of therapeutic modalities
designed to improve the patient’s quality of life by decreasing airflow
limitation, preventing secondary medical complications, and allevi-
ating respiratory symptoms. Successful implementation of a pul-
monary rehabilitation program usually requires a team approach, with
individual components provided by healthcare professionals who have
experience in managing COPD (e.g., physician, dietitian, nurse, res-
piratory therapist, exercise physiologist, physical therapist, occupa-
tional therapist, recreational therapist, cardiorespiratory technician,
pharmacist, psychosocial professionals). In COPD, pulmonary rehabil-
itation has documented benefits in exercise tolerance, dyspnea, and
health related quality of life. Additionally, it may reduce health care
utilization [36].
Given the generally progressive nature of COPD and the fact that it
is the third leading cause of death world-wide, clinicians should always
include end-of-life care discussions in their visits with patients with
advanced stages of this disease. These discussions should focus on pal-
liative efforts to improve quality of life, as well as assistance with ad-
vanced directives, advanced care planning, and referrals for hospice
and home care when needed.
COPD and chronic heart disease
Key points
• Patients with COPD and heart disease share a common risk
factor: cigarette smoking
• The use of a fixed FEV1/FVC ratio of <0.70 to detect airway ob-
struction instead of using lower limit of normal thresholds,
can lead to a misdiagnosis of COPD, especially in the elderly,
those with heart failure and those with low lung volumes; the
consequent can be unjustified use of bronchodilators in these
patients
• A greater extent of emphysema on CT scan and greater air-
flow obstruction are linearly related to impaired left ventric-
ular filling, reduced stroke volume, and lower cardiac output
• Reducing hyperinflation in COPD with long-acting bron-
chodilators results in improved cardiopulmonary performance
The heart and lungs share the same space in the thorax, and often
impairment of one can produce serious effects on the other. Addition-
ally, similar risk factors (e.g., cigarette smoking) frequently cause car-
diovascular disease and COPD in the same patient. Smokers have ten
times higher risk of developing lung cancer than nonsmokers and four
times the risk of developing COPD [37]. In a similar way, smoking in-
creases the risk of ischemic heart attack 1.5 times for ten
cigarettes/day smokers and 2 times for 30 cigarettes/day smokers [38].
Clinical symptoms and signs of COPD and chronic heart failure
(CHF) frequently overlap, so evaluation of cardiac versus pulmonary
disease in daily practice is often problematic and occasionally mis-
leading. Because of this, echocardiography as well as pulmonary func-
tion tests should be considered in every symptomatic COPD patient to
avoid potential misdiagnosis and subsequent inappropriate treatment.
Simply getting spirometry in patients with COPD is problematic, since
– at least in one health care setting – the number of COPD patients
without pulmonary function studies was greater than the number of
than 1% of all cases in the United States. Severe deficiency leads to pre-
mature emphysema at an average age of 53 years for nonsmokers and
40 years for smokers. Nearly 24 variants of the AAT molecule have been
identified; all are inherited as co-dominant alleles. 
COPD is a syndrome with several phenotypes. Patients typically
present with a combination of signs and symptoms of chronic bron-
chitis, emphysema, and reactive airway disease. Symptoms include the
following: i) Cough, usually worse in the morning and productive of a
small amount of colorless sputum; ii) Acute chest illness (exacerba-
tions); iii) Breathlessness: this is usually the most significant
symptom, but usually does not occur until the sixth decade of life; iv)
Wheezing: this may occur in some patients, particularly during exer-
tion and exacerbations. 
The severity of airflow obstruction remains a primary means of
staging COPD since the American Thoracic Society (ATS) provided cri-
teria for staging COPD based on: i) defining the presence of obstruc-
tion (ratio of FEV1 to forced vital capacity [FEV1/FVC] <70%); and ii)
determining its severity based on percent-predicted FEV1. ATS and
Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria
for assessing the severity of airflow obstruction (based on the percent
predicted post-bronchodilator FEV1 when the FEV1/FVC is <70%) are as
follows:
• Stage I (mild) - FEV1 80% or greater of predicted.
• Stage II (moderate) - FEV1 50-79% of predicted.
• Stage III (severe) - FEV1 30-49% of predicted.
• Stage IV (very severe) - FEV1 less than 30% of predicted or FEV1. 
However, staging systems based on spirometry have limited utility in
predicting mortality. The recognition that COPD is a systemic disease
has helped in developing criteria that are better at predicting mortality
than is assessment of airway obstruction alone. A widely-used system
for COPD prognosis is the BODE index (body mass index, obstruction
[FEV1], dyspnea [modified Medical Research Council dyspnea scale],
and exercise capacity [six minute walk distance]) [31].
Smoking cessation continues to be the most important therapeutic
intervention for COPD. Risk factor reduction (e.g., influenza vaccine)
is appropriate for all stages of COPD. Other therapeutic approaches to
management by stage include the following [23]:
• Stage I (mild obstruction): Short-acting bronchodilator as-needed. 
• Stage II (moderate obstruction): Short-acting bronchodilator as-
needed; long-acting bronchodilator(s); cardiopulmonary rehabilita-
tion.
• Stage III (severe obstruction): Short-acting bronchodilator as-
needed; long-acting bronchodilator(s); cardiopulmonary rehabilita-
tion; inhaled glucocorticoids if repeated exacerbations.
• Stage IV (very severe obstruction or moderate obstruction with evi-
dence of chronic respiratory failure): Short-acting bronchodilator as
needed; long-acting bronchodilator(s); cardiopulmonary rehabilita-
tion; inhaled glucocorticoids if repeated exacerbations; long-term
oxygen therapy (if criteria are met); consider surgical options such
as lung volume reduction surgery (LVRS) and lung transplantation.
COPD is commonly associated with progressive hypoxemia.
Oxygen administration reduces mortality rates in patients with ad-
vanced COPD [32], probably because of its favourable effects on pul-
monary hemodynamics. Noninvasive positive pressure ventilation
can provide significant benefits in selected patients with acute hy-
percapnic respiratory failure due to COPD, including a reduction in
the need for endotracheal intubation, reduced hospital stay, and a
mortality benefit [33].
Influenza and pneumococcal vaccination is a safe and effective
modality to improve outcome in COPD [34,35], presumably due to re-
ducing infections in susceptible patients. The pneumococcal vaccine
pimeEDITRICE
N
n c
om
me
rci
al 
us
e o
nly
[Monaldi Archives for Chest Disease 2017; 87:786] [page 5]
Proceedings
CHF patients without echocardiographic examination, indicating that
the typical cardiology workup is more objective than the pulmonary
workup of symptomatic patients [39].
According to ERS/ATS guidelines, a COPD diagnosis requires airway
obstruction confirmation by spirometry [40]. From a physiologic point
of view, obstruction must be considered when a forced expiratory
volume in one second to vital capacity (FEV1/VC) is below the lower
limit of normal (LLN, such as <89% in males <88% in females) [41].
The use of a fixed ratio such as an FEV1/VC <70% absolute value, as uti-
lized by GOLD guidelines, overestimates COPD occurrence in the eld-
erly because of the age-related reduction in vital capacity, with gender
differences (overestimation in males) [42]. Often in older males with
heart failure and reduced lung volumes COPD group “B” could be diag-
nosed using fixed ratio with misdiagnosis and unjustified use of bron-
chodilators [43].
The prevalence of CHF in COPD patients, excluding known coronary
artery disease, ranges from 0-16% in stable patients and from to 0-32%
in exacerbated patients [44]. Cardiovascular diseases are correlated
with COPD severity: the greater the airflow limitation the higher per-
centage of CHF patients with overlap of the two diseases [45]. From a
different perspective, CHF patients have seven-fold relative risk of
COPD. 
Very severe COPD often results in cor pulmonale, with elevated pul-
monary vascular resistance and secondary reductions in left ventric-
ular (LV) filling, stroke volume, and cardiac output. A greater extent of
emphysema [46] on CT scan and severer airflow obstruction are lin-
early related to impaired left ventricular filling, reduced stroke volume,
and lower cardiac output without changes in the ejection fraction. Fur-
thermore, hyperinflation in COPD or emphysema is associated with
reduced pulmonary vein cross-sectional area, suggesting impaired LV
filling. An impaired left ventricular diastolic filling pattern is, more-
over, independently associated with a reduced 6 minute walking dis-
tance. So left ventricular function is impaired in patients with severe
emphysema due to small end-diastolic dimensions and COPD and em-
physema on CT scan are associated [47] with reduced pulmonary vein
cross-sectional area. These findings suggest that impaired LV filling in
COPD, and also in emphysema may be predominantly due to reduced
LV preload from upstream pulmonary causes rather than intrinsic di-
astolic dysfunction, although cardio-pulmonary interactions are likely
complex. 
Very recently, Stone et al. [48] demonstrated that changes in cardiac
structure and function could be achieved reducing lung hyperinflation.
In stable, hyperinflated COPD, lung deflation with long acting bron-
chodilator results in structural alterations to both sides of the heart,
improved biventricular stroke volume, left atrial function, and pul-
satility within the pulmonary circulation. Right ventricular diastolic
function and filling pressure have strong influence on the functional
capacity in patients with COPD. The mechanism of the exercise intol-
erance is complex in COPD, thus it is difficult to identify the true con-
tributors. Nevertheless, and right ventricular diastolic function and
filling pressure have strong influence on the functional capacity in
these patients [49].
Ventilation is increased in CHF patients at rest and during exercise,
leading to an increase in inspiratory drive, while gas exchange is im-
paired in both CHF and COPD [50]. COPD had severe ventilation-per-
fusion mismatch, with differences between emphysema and chronic
bronchitis. Both the increased heart volume in CHF and often-present
pulmonary congestion and edema reduce lung volumes such as the
functional residual capacity (FRC) [51]. Due to this decrease in FRC,
many patients exhibit airway closure during tidal breathing, leading to
ventilation-perfusion mismatch and impaired gas exchange within the
lung [51].
During exercise testing it is possible to estimate ventilatory effi-
ciency using the minute ventilation (VE) to carbon dioxide production
(VCO2) relationship during exercise. In heart failure there is a dispro-
portionate increase in VE during exercise, while in COPD the relation-
ship is variable, with disproportionate increases in VE in mild-to-mod-
erate disease and disproportionate decreases in severe disease. More
recently, it was pointed out that the intercept of the VE/VCO2 slope is
related to dead space ventilation [52]. An increase in ventilatory inef-
ficiency, as manifest by a high intercept suggests coexistent COPD in
heart failure patients [53]. Nevertheless, high intercepts in patients
with largely preserved spirometry (GOLD spirometric stage 1), suggest
coexistent ventilation-perfusion abnormalities, explaining persistent
dyspnea and activity restriction [54]. 
In the overlap between COPD and heart failure, skeletal muscle per-
fusion is reduced to a greater extent than that expected by heart failure
alone. Given that these abnormalities are related closely to poor exer-
cise tolerance, increasing skeletal muscle O2 delivery and/or de-
creasing O2 demand might be of particular therapeutic relevance [55].
Overlap patients are particularly prone to respond to interventions
that increase skeletal muscle O2 delivery and/or reduce O2 demand. Po-
tential therapeutic options can, for example, include: A) Improving car-
diac output by non-invasive positive pressure ventilation and/or Heliox;
B) Adopting physical training strategies suitable for patients with se-
vere central cardiorespiratory constraints (e.g., small muscle mass
training); and C. Using drugs as sildenafil or nitrates to directly en-
hance O2 delivery-to-utilization matching with increased muscle blood
flow and/or lowered O2 cost of muscle contraction [55].
Cerebral blood flow and oxygenation are generally well-preserved in
COPD and increase with exercise [56]. However, in a small study,
overlap patients with COPD and heart failure decreased cerebral blood
flow during exercise. This drop was present despite preserved arterial
oxygenation. The authors speculated that this drop in overlap patients
may negatively contribute to clinically important outcomes such as ex-
ertional dyspnea, exercise tolerance, cerebrovascular disease, and cog-
nitive impairment. 
The overlap between COPD and CHF significantly reduces survival
and quality of life [57], so correct and well-timed diagnosis and
treatment are fundamental for the management strategies of these
patients.
Physical activity and long-term management 
of COPD patient
Key points
• Increases in exercise capacity from physical training do not
necessarily result in increases in physical activity
• Achieving a higher level of physical activity in COPD patients
is arguably a preferable goal over muscle training alone
• Physical activity, a measurable variable, should be promoted
in COPD patients as a beneficial lifestyle
Introduction
Physical activity (PA) is one of the major lifestyle-related health de-
terminants [58]. Epidemiological research has already produced con-
vincing conclusions about the health gains of being sufficiently active.
However, even if the impact of PA on public health is increasingly un-
derstood in scientific and academic circles, there remains a lack of po-
litical awareness (far less than that paid to tobacco and nutrition) and
recognition that comprehensive actions still need to be taken. PA is
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adapted to the single patient. Pulmonary rehabilitation is a compre-
hensive intervention based on a thorough patient assessment followed
by patient-tailored therapies which include, but are not limited to, ex-
ercise training, education and behavior change, and to promote the
long-term adherence to health-enhancing behaviors [36]. Increases in
exercise capacity in combination with behavioral change may also have
the potential to increase PA in these patients [36,72,73]. Indeed, given
the widened scope of rehabilitation in these patients (i.e., improve
symptoms, exercise capacity, and quality of life), outcomes assessment
has also broadened, allowing for the evaluation of COPD-related knowl-
edge and self-efficacy, including PA. Transferring exercise (i.e., effec-
tive training) behavior from a supervised clinical setting to a self-di-
rected leisure-time context poses a major challenge for most patients
with COPD who completed pulmonary rehabilitation.
The practical message is that simply increasing the exercise ca-
pacity of patients with COPD is insufficient to increase participation in
self-directed leisure time activity. Exercise capacity is thus considered
permissive of physical activity. Behavioral, social and environmental
interventions are now recognized as necessary to effect increases in PA
in COPD; these include mobilizing social support, using well-estab-
lished behavior change and self-regulatory techniques (self-moni-
toring, stimulus control, problem solving, relapse prevention manage-
ment, goal setting, self-reinforcement, providing feedback on perform-
ance and developing action plans), providing higher contact time or
contact frequency, and assessing and enhancing motivation to change.
Last, but not least, a deeper knowledge on how COPD patients perceive
symptoms limiting their PA in the every day life might help foster
strategies to enhance the effectiveness of these interventions.
The integrated care of the COPD patient
Key points
• Considering the high impact of COPD on quality of life, health
care utilization and mortality risk, our current medical man-
agement of this disease has considerable room for improve-
ment
• Current medical management of COPD often focuses on just
the respiratory disease, ignoring its systemic effects and
common co-morbid conditions
• Current medical management of COPD is usually fragmented
and uncoordinated; this is most problematic in the patient
with severe disease in the peri-exacerbation period
• An interdisciplinary, patient-centered approach to medical
management, along with coordination of care is necessary to
improve outcomes in at-risk patients with this disease; inte-
grated care deals with both these problem areas
The burden of COPD
Chronic obstructive pulmonary disease (COPD), besides being the
third-leading cause of death worldwide, imposes a substantial symptom
and functional status limitation burden on the patient and staggering
expenses on health care systems. Compounding this is the fact that we
do not have significant disease-modifying pharmacologic treatments,
using the traditional concept of disease modification as a reduction in
the rate of decline of airflow limitation [74]. However, pharmacologic
and nonpharmacologic interventions can have a appreciable effect on
reducing the frequency of exacerbations, which might be considered a
form of disease modification [74]. While optimal management of the
COPD patient must cover the entire course of the disease – and even
before the disease onset in modifying risk factors such as cigarette
generally defined as any bodily movement produced by skeletal muscles
that results in energy expenditure above resting level. Notwith-
standing, PA is a complex behaviour that can be characterised by type,
intensity, duration, patterns of activities, and symptom experience. The
term ‘physical activity’ means many different things to different
people. For public health professionals, it is a health-enhancing behav-
iour; others may see it as a phrase summing up a wide range of sports,
leisure pursuits or active travel. 
The human body evolved to move, and our physiological systems are
continuously working to balance the energy we expend through PA
with the energy we take in as food. A century ago, obesity was rare, as
people spent far more energy in manual work and walked more for
transport, and energy-dense food was less easily available. In the new
century, our lifestyles have changed and chronic diseases have in-
creased with aging population: most important, PA has been removed
from our lives. Throughout childhood, PA offers opportunities to de-
velop basic motor skills that are essential for healthy active living. As
we enter old age, PA becomes a critical component of a healthy, satis-
fying and independent life.
COPD and physical activity
In patients with COPD PA is reduced [59], and this reduction is re-
lated to important disease characteristics, such as airway obstruction,
dynamic hyperinflation, exercise intolerance, muscle weakness, sys-
temic inflammation, and coexisting cardiovascular diseases or other
comorbidities [60,61]. Furthermore, reduced levels of PA appear to be
linked with impaired increased future risk of hospitalizations, and
mortality [62-64]. Therefore, PA might have a central role within the
disease process, so its enhancement is desirable in medical practice,
and it deserves attention as a clinical outcome parameter [64]. Objec-
tive measurements of physical activity using motion detectors and val-
idated questionnaires have also helped increased interest in this as-
pect of health in COPD [65].
Interestingly, it has been recently shown that PA occurs early in the
natural course of the disease, with inactivity preceding both symptoms
and diagnosis by around 5 years [66].
The effect of changes in PA in COPD patients as well as in elderly
controls has been observed in a population-based study up to 17 years
[67,68]. Both COPD and controls showed an increased mortality risk
with low level of PA; however, improvement of PA level in those inactive
COPD patients at baseline did not change this risk. This might suggest
that assess and encourage PA in the early stage of the disease to main-
tain PA as high as possible is essential to improve prognosis.
Population-based epidemiological studies have assessed the longi-
tudinal effect of regular PA on lung function decline or COPD inci-
dence [69]. An inverse association between PA levels and the magni-
tude of lung function decline is present, although this association is
not consistent across population subgroups or physical activity vari-
ables. Potential explanations for such inconsistencies include selec-
tion bias, lack of adjustment for potential confounders, and lack of con-
sideration of changes in PA level during follow-up. International docu-
ments on COPD management suggest that PA is recommended for all
patients with COPD. However, there is little COPD-specific evidence to
support recommendations for PA, other than studies of pulmonary re-
habilitation [70]. 
Enhancing PA in COPD patients
Several interventions have been considered to improve PA in the
COPD population [71]. Notwithstanding, the mean achievable im-
provement in PA ranges from 10 to 40% of the baseline value at best,
which means that strategies should be more comprehensive and
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smoking in young people – much of the medical management of this
disease must focus, by current necessity, on the at-risk COPD patient.
This discussion will deal with the high-risk patient, defined somewhat
arbitrarily as that patient with a history of frequent exacerbations or in
the peri-hospitalization period for an exacerbation.
The at-risk COPD patient
Despite mind-staggering advances in science and technology in the
modern era, medical care for patients with chronic diseases such as
COPD – at least when using re-hospitalization as a criterion – is often
abysmal. For example, a landmark study by Jencks et al. [75], using
2003-2004 Medicare claims data demonstrated that almost one-fifth of
discharged Medicare beneficiaries (not just COPD patients) were re-
hospitalized within 30 days and 34% were re-hospitalized within 90 days. 
The discord between technology, on the one hand, and outcome, on
the other hand, is accentuated by the fact that considerable monetary
funds are spent on the medical care of elderly patients, who are most
likely afflicted with chronic disease: medicare claims data in 2014 in
the United States showed a peak expenditure of $43,453 per individual
in 73 year old individuals! [76]. 
These statistics on health care utilization have not changed sub-
stantially over the past decade or so since the publication of the Jencks
article, making this problem still relevant to the hospitalized COPD pa-
tient in 2016. For example, quarterly assessments of any-cause 30-day
re-admission rate for COPD in US hospitals typically range from the
mid-teens to the mid-twenties. Health status is severely decreased
during the COPD exacerbation, and it typically remains impaired for
several weeks following the onset of the event [77]. Additionally, func-
tional status, using directly-measured physical activity as its criterion,
remains decreased for at least 2-3 weeks after onset [78]. Finally, mor-
tality risk is increased after the first severe (i.e., hospitalized) COPD
exacerbation, and goes up dramatically after the second [79]. 
Common system problems with the COPD patient
hospitalized for an exacerbation
As stated above, the COPD patient hospitalized for an exacerbation
generally has severe disease, increased symptoms, marked functional
limitation, increased likelihood of having co-morbid conditions, a much
greater risk of being hospitalized again in the near-future, and a higher
mortality risk. Patients in the hospital and recently discharged following
exacerbations have accentuated medical needs, as outlined below.
• The hospitalized COPD patient’s medical care, because of the ur-
gency of the situation, necessarily must focus on the acute problem,
leaving little time for chronic disease management.
• Little patient-centered and holistic care is given in the hospital and
peri-hospital period.
• Single disease guidelines often fall short in achieving desired goals
in the complex, multi-morbid, hospitalized COPD patient.
• Fragmented medical care from well-meaning and accomplished prac-
titioners is often provided.
• There is often no one health care professional to take charge
throughout the hospitalization and peri-hospitalization period.
• Educating patients often takes a second place to the urgency of the
situation and the need to discharge patients promptly. 
• Inadequate instructions are given to the patient at almost every
point in care; often these instructions are computer-generated and
impersonal.
• Often the mechanism in place is inadequate for ensuring proper
medications after discharge.
• No planned transition of care from the hospital, to the home, and
(eventually) into the community.
Reasons behind this high impact of COPD on health
status, health care utilization and mortality
There are undoubtedly multiple reasons behind the high symptom
burden, functional and health status limitations, high health care uti-
lization and high mortality in the at-risk COPD patient, as defined
above. A listing of some of the problems includes:
i) The COPD patient is usually hospitalized for about 4-5 days, yet the
exacerbation that led to that particular hospitalization typically
lasts 3-4 weeks. Thus, the patient has not reached baseline status
at the time of hospital discharge, yet the intensity of care drops off
precipitously at this point in time. 
ii) COPD exacerbations tend to cluster temporally [80], putting the
discharged patient at-risk not only for deterioration in health
status from the index exacerbation but also at high risk for a
second one. In general, the strongest variable predicting a 30-day
hospital readmission in COPD is a history of a hospital admission
for this condition within the past year [81]. 
iii) The COPD patient in the peri-hospitalization period needs care
based on both the acute care and chronic care models of disease
management. Although attempts are underway to change the de-
livery of care, our current system of COPD management for the
hospitalized patient reflects the ‘tyranny of the urgent’ [82], with
most clinical resources dealing the necessity of acute intervention
for the very ill patient. 
iv) The complex problems of the at-risk COPD patients, with severe
disease, profound systemic effects, insufficient self-management
skills, often-lacking lines of communication, and frequent, severe
co-morbidity is best handed by an interdisciplinary team; this is
often not present in routine management.
v) The emphasis of returning the discharged COPD patient back to
the care of primary care professional can be a double-edged sword.
Certainly, the primary care provider must be engaged to realize
the full benefits of any comprehensive approach. However, in the
peri-hospitalization period, the complex COPD patient with se-
vere, unstable disease, often major changes in medical treatment,
and with common co-morbid conditions (such as CHF) is best
managed at least temporarily by the interdisciplinary team that is
acquainted with this individual from the index hospitalization.
Thus, proper transitioning from acute care to chronic care, incor-
porating and refining both approaches, is essential to optimal
management of this patient. 
vi) Current medical care for the complex patient with exacerbations
of chronic disease such as the COPD patient is highly disjointed.
In many cases the COPD patients cannot name their hospitalists.
There is no “go-to” individual to call. The primary care physician
is typically “out of the loop”: for example, in the Jencks paper
mentioned above [75], about one-half of the Medicare patients
who were re-hospitalized within 30 days had apparently not seen
their primary care provider over this interval. Furthermore, there
is little communication among crucial health care providers man-
aging patients over this very-critical post-discharge period. In our
experience, even with electronic medical records, the primary
care provider often does not know that his/her COPD patient had
been even admitted to the hospital. Clearly, continuation of med-
ical services is crucial during the vulnerable post-hospitalization
period.
vii) Patients with COPD, despite aggressive attempts at collaborative
self-management education from experienced professionals, often
do not become successful self-managers, and it is these unsuc-
cessful self-managers who are at particularly high risk for subse-
quent health care utilization [83].
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Self-management
Supported self-management in COPD includes efforts at educating
the patient to become more efficient at practices that are involved in
self-efficacy. This typically includes promotion of a healthy lifestyle (in-
cluding smoking cessation, exercise, physical activity any proper nutri-
tion), education on the early recognition and prompt treatment of the
exacerbation, and better adherence to the often complex treatment
regimen. This intervention has had mixed success when tested criti-
cally in randomized trials [92]. Part of this inconsistency may be due
to the finding that only about 40% of patients with COPD when given
self management education in selected trials actually become suc-
cessful self-managers [83]. Adding to this is the under-emphasis of
care coordination in some self management trials. 
Pulmonary rehabilitation
Pulmonary rehabilitation, which includes self management educa-
tion and exercise training, has demonstrated positive outcomes across
several areas, including improvement in symptoms, exercise capacity
and health status [36]. Additionally, when provided shortly after a hos-
pitalization for an exacerbation, it appears (from a systematic review)
to be related to reduced health care utilization, and even mortality
[93]. This comprehensive intervention provides many of the compo-
nents of integrated care, but does often fall short with respect to care
coordination across settings.
Health coaching
A recently-described model of health intervention, named health
coaching by the investigators, utilized motivational interviewing tech-
niques, self management education, and limited care coordination. This
intervention, which perhaps was incorrectly named since it incorporated
more than health coaching, did produce impressive positive outcomes,
including reduction in health care utilization, in the trial reported [94]. 
Patient-Centered Medical Home
This model of care was originally designed to reorient medical care
back to the primary care provider. It includes the following components: 1)
care across the course of the disease, prevention and wellness, acute care,
and chronic care; 2) A holistic approach to medical management that fam-
ilies as well as the patient; 3) Coordination of care across the entire health
care system,; and 5) Greater accessibility of services [95,96]. As a concept,
therefore, this comes very close to the integrated care model. 
Delivery system design and decision support
Key points
• The Chronic Care Model has become the paradigm for effec-
tive treatment of persons with chronic disease; this model
has four components, self-management; delivery system re-
design (eliminating silos of care); decision support (e.g.,
practice guidelines); and information systems
• Guideline development should have a multidisciplinary col-
laborative framework, with central coordination and be free
of proprietary influence
• Unfortunately, clinical practice guidelines, as they currently
exist, do not adequately address co-morbid conditions that
are common to COPD
Delivery system design and decision support are two key compo-
nents of integrated care (IC), also known as the chronic care model of
disease management (CCM). he other two components are self-man-
A very brief summary of previous studies of practice
redesign for COPD
Treating the complex patient with COPD, especially in the peri-hos-
pitalization period is a challenge both to that patient’s health care
providers and to the system. It certainly involves much more than
simply prescribing bronchodilators. Patients admitted with COPD ex-
acerbations or who have had frequent exacerbations often have severe
primary lung disease. Beyond treating the lung disease, including air-
flow limitation, hyperinflation, mucus hypersecretion and gas ex-
change abnormalities, consideration must be given to recognizing and
treating its often prominent systemic consequences and frequent co-
morbidities. Systemic effects are increased during exacerbations, and
frequent comorbidities also contribute to total disease burden [84,85].
As stated earlier, current care is often reactive, by necessity focusing
on the problems associated with the exacerbation [86]. Even then, the
pervasive nature of the exacerbation often requires an interdiscipli-
nary approach that may not be available to the institution. Finally, for
optimal care, proactive management is necessary to provide the pre-
ventative, educational, social services to optimize outcomes.The
chronic care model [82,87], which is now about 15 years old, was de-
veloped to address the needs patients with chronic illness. This model
has six components: i) self management support; ii) clinical informa-
tion systems; iii) delivery system redesign; iv) decision support (guide-
lines); v) health care organization; and vi) community resources
[82,87]. These components are designed to tailor therapies to the in-
dividual patient and integrate services across settings. Most new com-
prehensive approaches to management of COPD have the chronic care
model at their root. 
A definition of integrated care from an American Thoracic Society
workshop defined it as, “The continuum of patient centered services or-
ganized as a care delivery value chain for patients with chronic condi-
tions with the goal of achieving the optimal daily functioning and
health status for the individual patient and to achieve and maintain the
individual’s independence and functioning in the community” [88]. As
a concept of care, integrated care is multidimensional, having system,
organizational and clinical levels [89], making it somewhat confusing
when specific aspects are not clearly delineated. Clinical integrated
care for the COPD patient, which pertains to this discussion, is based
on the chronic care model, with – arguably – additional emphasis on
organizational and transitional care. Examples of clinical integrated
care include a holistic approach, addressing the burdensome symptoms
and disability from the disease, its systemic and comorbid conditions
and from its therapy; management strategies over the entire trajectory
of COPD, such as smoking cessation, promoting regular exercise and
activity, optimizing pharmacotherapy, collaborative self-management,
palliative therapy and hospice care; and (not to be overlooked) coordi-
nation of care among health care providers. 
Other approaches to medical management have had elements of the
entire package of clinical integrated care. Some examples include:
Bundling of services
Pre-discharge bundle of services at the time of the COPD discharge
home includes, in different studies, a review of medications, educating
on inhaler technique, assuring the patient has access to medications
upon discharge, educating on medication adherence, and assuring the
patient has prompt follow-up with health care providers. This type of in-
tervention, although it makes great sense, has had limited success in
reducing re-hospitalizations [90] – possibly because the items chosen
for the particular bundle may not have been the ones needed in this sit-
uation, possibly because the positive signal from such an intervention
may have not been sufficient to produce detectable change [91]. 
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agement and clinical information systems [97]. In a systematic review
of approaches to CCM, Adams and colleagues [98] noted that the clin-
ical studies in which healthcare use was reduced had included at least
two of these following four IC components: 
1. Self-management techniques that increase the patients’ ability to be
the manager of their own condition.
2. Delivery system design to reorganize the clinical team to provide pa-
tients with prompt access to a knowledgeable health care provider
3. Decision support to enable clinical management to be guideline
based and supported through provider education.
4. Information systems, to enable disease tracking, registries and rapid
feedback to the point of care.
This article will comment on delivery system design and decision
support. 
Delivery system design
In many jurisdictions, healthcare is funded in silos in which primary
and secondary care clinicians, hospitals and community resources op-
erate in isolation from each other. Silo activities may function satis-
factorily during episodic reactive acute care but do not optimize the on-
going needs of those with chronic complex conditions who require sup-
port across the spectrum of care at different times and from different
locations. Not only is a silo system difficult for the patient to navigate
but it enables medical error, under-diagnosis, inadequate monitoring
of chronic conditions, loss of patient and caregiver preference, insuffi-
cient education to participate in self-management, omission and dupli-
cation of services [97]. In essence, it has been associated with poor
quality care, high costs, low patient as well as provider satisfaction.
It is important to CCM system design that there be a clear under-
standing of the roles and tasks within a multidisciplinary healthcare
team. Team functions and practice systems need to be reorganized
such that appointments and follow-ups are scheduled to meet the needs
of the chronically ill patients. Planned interactions to support care, clin-
ical case management for complex patients and regular follow-up by
the care team should include a focus on function as well as prevention
of exacerbations and secondary complications. Care must also be un-
derstandable to the patient as well as being culturally appropriate. The
entire system should be overseen by care networks or local advisory
groups consisting of patients, healthcare providers and healthcare
funding agencies. Many of the components of the CCM model, such as
an action plan for exacerbations, patient education, self-management,
supervised exercise training and psychological as well as social support
are increasingly found in pulmonary rehabilitation programmes. In
COPD, the clinical reach of the CCM model extends further, beyond
these modalities to address issues of ongoing support that include long
term follow-up and maintenance [99]. The extended rehabilitation ca-
pability may then function conceptually either as a bridge between the
acute care hospital and the community, or as a buffer, accepting enrol-
ment directly from the community with the intent of avoiding the re-
ducing the requirement for hospitalization. 
An early example of CCM was the guided care model [100], in which
a registered nurse enrolled patients with COPD from the offices of sev-
eral primary care physicians. The nurse carried a full assessment in-
cluding medical, cognitive and functional status and then developed an
evidence based care guide together with the primary care physician,
which was entered into an electronic database. This guide was dis-
cussed with the patient and the caregiver and a simplified action plan
was displayed at home. Those enrolled underwent a 15 hour lay led
course in disease self-management. Patients were monitored with
monthly calls and coached using motivational interviewing. Other func-
tions included coordinating transitions between sites and providers of
care, updating the electronic medical record, communicating with
physicians, educating caregivers and assistance accessing community
resources [100]. This model of care has been reported to result in a de-
crease in resource utilization and an increase in patient and provider
satisfaction [101-105]. Several other models, described elsewhere,
have used similar elements and have observed a positive impact on
healthcare utilization, with fewer hospital admissions among the study
group [106-108].
Decision support
Decision support involves embedding evidence based clinical practice
guidelines (CPG) into daily practice. These should promptly available
and shared with patients and their families to encourage participation.
Provider education and integration of approaches to treatment among
specialists, generalists and primary care, are also enabled through deci-
sion support. CPGs should be considered as part of clinical judgment.
However, as stated in the National Clinical Guideline Centre (NICE)
guidelines for COPD management, they should not override healthcare
professionals making informed clinical judgments based in part on
product characteristics of medications being considered [109]. CPGs
often do not address multi-morbidity. Therefore, a busy practitioner at-
tempting to implement several CPGs may have to balance increased
risks of adverse drug interactions, patient preferences and the time im-
position on the patient for monitoring [84]. A vision statement on
guideline development for respiratory disease following an American
Thoracic Society – European Respiratory Society workshop on guideline
development [110] noted the need for a multidisciplinary collaborative
framework, with central coordination, funded free of proprietary influ-
ence. It was suggested that the evidence be shared among an interna-
tional committee of authors who could jointly review the evidence and
the guideline recommendations. Questions answered in the guidelines
should be those important to patients, clinicians and other stakeholders.
Guideline development should include standardized metrics to grade
the quality of the evidence and the recommendations. Committees in-
frequently address the challenge of co-morbidities or provide advice on
how clinicians, patients and others might implement them. For CPG de-
velopment to be successful, in addition to ensuring rigorous standards
by assembling the most knowledgeable clinicians, there does need to be
expertise in guideline methodology. The vision statement also encour-
ages guideline development committees not to hesitate in considering
new ideas, diverse perspectives and unique contributions. 
In 2008, the New England Healthcare Institute reported on barriers
and strategies that might influence physician adherence to CPG [111].
This publication noted the importance of evidence based CPG as the
“rules of the road” for physicians. These guidelines are the key to im-
proving quality, outcomes and cost effectiveness of healthcare. To ad-
dress the gap between agreed standards of care and actual practice,
four categories of barriers were noted; payment (in some healthcare ju-
risdictions the metrics of care include volumes rather than outcomes,
so there is little financial incentive to change behaviour); information
technology (insufficient information access at point of care limits sup-
port for clinical decision making); physician culture (physicians tend
to rely on their own judgment and receive very little feedback on their
process of decision making); and current development (lack of trans-
parency in CPG development, lack of trust in the guideline, lack of
guideline flexibility in clinical practice and failure to reflect complexity
of practice). A number of recommendations were made as to practice
changes that might enhance the use of CPG. The authors noted that
guideline use varied very little with age (≤40 years compared with >40
years) and that most physicians described themselves as “light” guide-
line users.
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a structured delivery mechanism. Programmes that offer at least two
components of the Chronic Care Model have also been shown to re-
duce hospitalizations [98]. There is some suggestion, though, that
such comprehensive approaches have greater benefit to those patients
most at risk from hospitalizations. The delivery of programmed care to
those patients in primary care who are not at great risk from hospital-
ization may not have much to gain [113]. The position of digital solu-
tions to care provision also remains uncertain. Tele-monitoring alone
does not seem to offer any significant benefit when added to an ex-
isting effective programme [114]. In some parts of the world digital
approaches to care delivery have been successful while in others this
has not been the case.
We usually consider integrated care for COPD from the standpoint
of provider structures. It is important to realize that COPD should be
an area of interest to commissioners or payers. COPD imposes a sub-
stantial healthcare burden in terms of premature mortality and re-
source usage. It is associated with late inaccurate diagnosis and
there are large variations in the quality of care. Commissioners
therefore need to take an interest in developing clinical pathways that
consider the whole population and also provide value for the tax
payer. In many countries there is a barrier between primary care and
access to a specialist. 
From a patient’s perspective, treatment by a specialist would always
be preferable. On the other hand, for a system to deal with a common
condition like COPD most clinical contact will have to take place in a
primary care setting. For far too long we have tolerated a system where
disease-specific expertise is locked behind a referral barrier which pre-
vents access for many patients and transfer of knowledge and skills
across the system. In effect, specialists may become a barrier to
progress to improving access to expert care so a change in the model is
required [115]. There are several ways that commissioners can help to
improve the system by encouraging vertical integration. Firstly, spe-
cialists can enhance the skills of general practitioners and other pri-
mary care staff by taking part in multi-disciplinary meetings, webinars
or virtual clinics. It is also possible to move away from the stereotype of
hospital specialist and general practitioner towards a model where spe-
cialists work in and acknowledge their responsibility towards the com-
munity that they work in. In the UK, it is becoming increasingly
common to appoint respiratory physicians with a responsibility for
services in the community as well as their base hospital. 
Traditionally, we think of commissioning services for COPD in
terms of the needs of individual patient. This approach does not nec-
essarily ensure that each patient necessarily ends up receiving the
right care at the right time or place. Population level commissioning is
an approach that can produce the right care for each patient and si-
multaneously provide the best value for the system. This approach re-
quires the ability to stratify the population by risk or severity and also
ensure that there is a sufficiently robust clinical commissioning
pathway so that people are treated in the correct environment. Other
specialties such as diabetes have become more experienced in such
population approaches and use clear clinical pathways to identify
where patient are best managed. It should be possible to do this easily
with COPD. For example there are clearly some things like lung
volume reduction assessment, respiratory failure and advanced dis-
ease that require the technical services that exist only in hospitals.
Other services such as pulmonary rehabilitation, self-management
training or spirometry can be undertaken in a community setting.
Case finding, medicines management and influenza immunization
can be conducted in the local surgery. Some things like smoking ces-
sation need to be available in every domain. The commissioner’s role
is to design and broker solutions along these lines that suit the char-
acteristics of the population. 
In many jurisdictions, the healthcare system fails to meet the
needs of patients with complex chronic conditions and multi-mor-
bidity. System redesign is required to decrease silo care and provide
prompt access to healthcare professionals across different locations
at different time points in the disease. Practice guideline committees
should be international and have standardized metrics. They need to
address the issue of multiple chronic conditions as well as the varia-
tions in treatment responses. Guidelines should also provide the op-
portunity for modification based on local cultural, political and eco-
nomic factors. 
Integrated care for COPD: patients versus systems
Key points
• Clear terminology is needed in the area of integrated care for
the COPD patient
• Good COPD care is multi component, multi professional and
coordinated
• Patient engagement (and involvement) is critical
• Chronic care models seem to work
• Technology alone is not the solution
• Population level commissioning is the way forward
When the subject of integrated care for COPD is discussed, it is as-
sumed that we are all agreed on a definition. In fact, this is not the
case, and a review of the literature reveals many variations on what we
mean by the term integrated care. The British Thoracic Society has re-
cently published a statement on the subject and defines integrated care
as “The best possible care for the patient, delivered by the most suitable
health professional, at the optimal time, in the most suitable setting”
[112]. While no one would disagree with this idealistic sentiment the
definition does not explain how such an outcome could be delivered. In
an attempt to clarify the situation it is possible to consider aspects such
as the components of good care, the delivery of care through coordi-
nated programmes and the commissioning of appropriate care path-
ways by payers.
The clinical guidelines available today recognize that COPD care re-
quires a modular approach. The components include prevention
(smoking cessation), drug therapy, rehabilitation, exacerbation plan-
ning, self-management training and – eventually – palliative care. In
addition, most patients with COPD will have other co-morbid condi-
tions that will require appropriate attention. While not every patient
will require the same selection of treatment options, it is important
that the individual patient has their need for each component assessed.
These days it is very unlikely that a single health professional will be
responsible for the total care of the patient; therefore, the delivery of
care will require a multi-professional team as well as involvement of
the patient. In the context of delivery, integrated care can be considered
to be multi-professional care that crosses the traditional boundaries of
primary and secondary care (vertical integration). Such an approach
has been shown to reduce hospitalizations and improve symptoms. In
some circumstances the integration may extend to social care and even
local government.
It is desirable for the delivery of integrated care to be coordinated
and de-fragmented. Ideally this should be by a single provider capable
of providing all necessary aspects of care and involving the patient at
the center of decision making. The most common theoretical model of
care in this respect is the Chronic Care Model [97]. In this case, the
knowledgeable dialogue between patient and health professional is
supported by information technology and clinical guidelines as well as
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So far, we have not mentioned the patient’s role in their care. One
of the principles of the chronic care model approach is that the pa-
tient is not only at the center of care but also that they take an active
and informed part in decisions about their care. One of the corner-
stones of the political reforms of the health service in England ear-
lier this decade was the mantra “no decision about me without me”.
For integrated care services to fulfill their potential the patient must
be aware and informed about their condition and have the know-
ledge and confidence to demand the best from their health care pro-
fessional team. Unfortunately, we are still some way from achieving
this ideal.
Self-management and health information
technology
Key points
• Self-management education aims a sustained, adaptive be-
haviour change in targeted areas
• Systematic reviews have shown positive outcomes for COPD
patients undergoing self-management interventions
• Health information technology can improve lines of commu-
nication among patients and caregivers
Introduction
Many countries have recognized and endorsed the need for self-man-
agement education within national standards of care. The premise is that
if patients receive effective support/coaching they can be empowered to
adopt the behaviour needed to cope with their disease on a day-to-day
basis. By doing so, medication adherence will be improved, exacerbations
will be better managed, healthy behaviours (exercise/physical activity)
will become second nature, and many of the poor outcomes related to
chronic disease can be averted [116].
Systematic reviews have shown positive outcomes for COPD patients
undergoing self-management interventions. A recent Cochrane review
[117] demonstrated that self-management interventions led to a lower
probability of respiratory-related hospitalization (odds ratio 0.57, 95%
CI 0.43 to 0.75, nine studies, 1749 participants).There was also an ef-
fect of self-management interventions on improving health status (St.
George’s Respiratory Questionnaire total score, mean difference -3.51,
95% CI -5.37 to -1.65, 10 studies, 1413 participants). 
However, challenges remain understanding why some self-manage-
ment interventions succeed while others fail. The answer to this ques-
tion cannot be found by simply adding up the contents of successful in-
terventions while subtracting the contents of the unsuccessful ones.
After looking more closely at the trials, it becomes evident that pro-
grammes more likely to be effective have the following characteristics:
• Self-management education aimed at behaviour changes, targeting
a patient’s goal.
• Timely access to health care.
• Support/coaching by health care professional such as a case manager.
• Carefully considering disease severity and comorbidities.
Self-management education intervention aiming 
at behavioural changes
The findings from some studies suggest that successful self-man-
agers (i.e., those patients who follow self-management training in-
structions) stand to benefit from the self-management education. In
a study by Bucknall and colleagues [118], 42% of patients with COPD
given self-management training became successful self-managers;
this subgroup did have a significant reduction in the primary end-
point of the study (hospital admissions). In a study by Bischoff and
colleagues [119], 40% of patients with COPD were adherent to their
written action plan for the exacerbation, and, likewise, this subgroup
improved with respect to a more rapid recovery of their respiratory
symptoms. 
There may be many reasons to explain the low rates of COPD pa-
tients becoming successful self-managers. It is noteworthy that the ma-
jority of patients (>50%) in the studies had only one exacerbation
during the follow-up period – providing too few opportunities to imple-
ment the self-management skills taught during the initial intervention.
Another reason could be a failure to intervene: the self-management
training intervention was not properly constructed or implemented to
change self-management behaviour or outcomes. An example of this
would be in the negative trial by Fan and colleagues [120]. In this
multi-center study, the self-management educational intervention was
implemented according to protocol, in that 87% of patients in the in-
tervention group completed all four individual self-management educa-
tion sessions; and case managers covered 77-89% of the educational
items and follow-up telephone contacts. However, a closer look at how
the intervention was received by patients reveals that they failed to use
the self-management skills that they were taught: they didn’t initiate
use of antibiotics and/or prednisone any earlier than those in the usual
care group. Furthermore, although patients were instructed to call their
case manager if they experienced an exacerbation that required med-
ication, calls were made in only 4.5% of patients in the intervention
group. In contrast, case managers in a positive trial of self-manage-
ment by Bourbeau et al. [106] were contacted by patients in 48% of ex-
acerbations. 
In order to be successful, a self-management intervention has to lead
to behaviour change in those behaviours targeted by the intervention.
Most important, it is the process of supporting self-management, which
refers to the strategies, techniques and skills used by healthcare
providers (typically case managers) to instrument patients with the
knowledge, motivation, confidence and skills required to effectively
self-manage their disease. 
Another important problem has recently emerged: There is concern
that the health benefits from such self-management programmes in
COPD could be counterbalanced by an increased mortality signal from
the results of one study in particular [120].
It is clear that self-management should be carefully targeting dis-
ease severity and comorbidities. We have to look to find potential solu-
tions to improve self-management intervention to increase patient ad-
herence with respect to self-management skill/behaviors, to insure
timely access to the health care professional and physician and to
better target disease severity that it is done safely.
Health information technology
Health information technology is increasingly seen as a key tool for
improving the quality and efficiency of care. It includes electronic health
records; personal health records; use of personal digital assistants;
health information exchange; computerized order entry systems; 
e-prescribing; and disease-specific or population-based registries. 
Health care systems are counting on health information technology
to facilitate the implementation of chronic disease management pro-
grammes, thereby reducing preventable hospitalizations and adverse
events. Specific to COPD, data on the utility on health information
technology to the management of this chronic respiratory disease are
limited and suffer from several problems, including small patient num-
bers, variable intensities of monitoring, and the lack of pre-determined
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disease has been developed and implemented in the primary care
practice in Montreal, Quebec, designed to assist health care profes-
sionals in treating COPD patients. The registry includes different
components: patient, inscriptions, diagnostic, quality indicators,
medication and lab. The following specific indicators of are moni-
tored in the practice:
• Physician (practices): Written action plan and access to prescription
with communication of health care professional (case manager).
• Patient (outcomes): Specific behaviours (≤3 days recognition of the
exacerbation followed by appropriate actions; health-related quality
of life.
• Health care system (outcomes): Primary care provider unscheduled
visits, emergency department visits, hospital admissions.
Implementation of this registry has made it possible to identify those
patients who had difficulty in managing COPD exacerbations. Imple-
menting a programme with an interdisciplinary approach (involving a
nurse and/or a respiratory therapist with the family physician) could
then bridge this gap. Data are collected on specific aspects of the man-
agement of exacerbations, including its early recognition and treat-
ment and actions taken to prevent emergency department visits and
hospital admissions. 
In the year before implementing the programme only 10% of patients
with exacerbations had a written action plan, leading to delays in con-
sultations and treatment. After the implementation of the programme,
most of the patients with a history of exacerbations had both a written
action plan, and a nurse or a respiratory therapist to coach them in its
implementation Two-thirds of the patients at 3 and 6 months reached
pre-defined quality indicators of adopting the proper behaviour in self-
managing exacerbations; this included following the action within 3
days of symptom worsening and adjusting action (calling the case man-
ager) if not improving within 2 days.
These examples suggest that health information technology has a
potentially important role in improving outcome in COPD. However, in
order to make progress, health information technology has to be well-
defined with respect to aims, process and outcomes. Its rationale must
be more than simply good intention, and well-designed studies are
needed to provide more useful data in this area. 
Integrated care for patients with COPD in Italy
Key points
• The estimated prevalence of COPD in Italy ranges from 4.5%
(general population) to 6% (age 46 and 55 years) to 11%
(those over 55 years old)
• The need to improve care of COPD through integrating serv-
ices has led to several projects in Italy; several research proj-
ects are still in progress
• Greater accessibility to pulmonary rehabilitation, greater em-
phasis on education, and telemedicine assistance are seen as
important components of integrated care
The estimated prevalence of COPD in Italy ranges from 4.5% of the
general population, up to 6% of individuals aged between 46 and 55
years, and 11% of those over age 55 [123]. Differences in reported
prevalence rates depend on diagnostic criteria and regional differ-
ences, with higher prevalence rate in males and ex-smokers [124].
COPD is a risk factor for several comorbid conditions, such as heart
disease, and non-psychotic mental disorders, included depression,
with higher impact in elderly patients [125]. Several variables are
treatment plans. Recently, the American College of Chest Physicians
and the Canadian Thoracic Society guideline on Prevention of Acute
Exacerbations of COPD concluded that, “telehealth compared to usual
care does not result in prevention of acute exacerbations (ER, hospital
admissions) over 12 months” [121]. Thus, clearly more information on
indication, implementation and setting is needed to make this inter-
vention successful. Health information technology has been long on
promises and short on details. We need more properly designed
studies.
Despite the limited support from the existing evidences in COPD
management, health information technology is expected to play a crit-
ical role in improving respiratory chronic disease outcomes. There are
several potential roles of health information technology: 
• Providing personalized support integrated care in chronic disease
management.
• Enabling decision-support for personalized evidence-based treat-
ment.
• Permitting chronic disease registries to be created to identify, mon-
itor (outcomes and practices), target at risk populations. 
Health information technology can be simple or complex. Simple
systems include clinical intervention with single feature, such as au-
tomated telephone contact, email communication, or website or
videoconference access. Complex systems include clinical interven-
tions that have more than one single component, such as combina-
tions of email communication, videoconference, web site, and tele-
health. 
Providing personalized support integrated care 
in chronic disease management
The COPD Patient Management European Trial (COMET) provides
an example of how it might be possible to use health information tech-
nology to support a self-management education intervention [122].
This trial includes 345 patients from 33 centers in 4 European coun-
tries. The objective of this pragmatic trial was to evaluate a multi-com-
ponent home-based COPD self-management programme, Living Well
with COPD (translated in 4 languages and adapted for the trial), com-
pared to usual care on all-causes hospital days in severe COPD pa-
tients over 1 year follow-up. The programme involves self-manage-
ment education and health coaching by case managers. Beyond its im-
plementation across culturally-diverse countries with distinct health
care systems, the combination of its self-management educational
programme with an e-health platform is novel. Key components of the
e-platform are: 1) Weekly/daily reporting by patient with automatic
analysis of clinical symptoms through an electronic data system; 2) A
dedicated vocal server to early detect and treat exacerbations; and 3)
Worsening of clinical status triggers an alarm, leading to a standard-
ised nurse intervention and transmission to the referent hospital
physician for a medical decision. Another methodological aspect of the
study is the attention implementing quality assurance with respect to
the regular training of the health care professional case managers,
standardization of the educational programme, and support by the
case managers during the study. Furthermore, this study does not
limit assessment to only trial outcome measures such as patient
health and hospitalizations, but also includes process measures (e.g.,
patient acquisition of skills and behavioural changes). The intent is to
gather information that could facilitate the interpretation of trial out-
comes that are still to come. 
Chronic disease registries
Health information technology could also permit chronic disease
registries. An example is a standardized, web-based registry for chronic
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identified as factors influencing COPD life expectancy, including
smoking, severity of dyspnoea, age, exercise capacity, body mass
index (BMI), exacerbation rate, comorbidities, and quality of life.
Severity of COPD (as assessed by Global Initiative for Chronic Ob-
structive Lung Disease [GOLD] stage), comorbidities and low BMI
may also predict mortality or hospitalization risk in an Italian popula-
tion [126]. 
Administrative data derived from hospital admissions and phar-
maceutical prescriptions may lead to underestimation of COPD
prevalence or incorrect identification, because patients suffering
from COPD usually receive diagnosis and treatment as outpatients,
and hospital admissions predominantly occur only in the most se-
vere stages. Epidemiological data from general practitioners (GPs)
data bases showed good identification of COPD subjects and consis-
tency with prevalence data from National Institute of Statistics
(ISTAT) surveys [127]. A recent Italian study reported a 3200 av-
erage year cost to manage COPD patients, with a 20% increase com-
pared to a study conducted in a similar population in 2008
[128,129]. Direct costs were mainly represented by hospitalizations
(67.2-70.7%), and occurrence and type of exacerbations were the
main drivers of direct health care cost. In a secondary data analysis
of healthcare administrative databases of the Lombardy region, two
and half years after a hospitalization health care resource consump-
tion was about 6700€, along with an increased risk of relapse of ex-
acerbation and mortality [130].
In Italy, the Chronic Care Model has been widely implemented in pri-
mary care since 2009. National and regional policies were until now ad-
dressed to the definition of integrated diagnostic and therapeutic path-
ways of care for several chronic conditions (including COPD) through
collaboration among hospital and community services [131]. Even if an
increase of economic resources consumed for outpatients was ob-
served in the recent years, further changes are claimed to increase the
capability of territorial management of moderate-to-severe COPD pa-
tients [128,132,133]. 
Adequacy of drug prescription, promotion of patient’s treatment ad-
herence, pulmonary rehabilitation, and individualized long-term treat-
ment strategies are proposed as interventions to decrease the rate and
severity of exacerbations of COPD [132]. The prevention and prompt
treatment of COPD exacerbations should include the reduction of risk
factors (smoking cessation, vaccination), inclusion in programmes of
respiratory rehabilitation, and promotion of self-management strate-
gies. Collaboration of hospital and community services aimed to the
health maintenance and prevention of hospital admissions is proposed
in the National Chronicity Plan being developed by Italian Ministry of
Health [134]. Integrated diagnostic and therapeutic pathways of care,
intermediate levels of care between hospital and primary care and pul-
monary rehabilitation are among the objectives to ensure that the pa-
tient be diagnosed and managed in the community and referred to the
specialist when appropriate. 
However, there are differences among regions, and some other crit-
icisms still hinder the widespread application of integrated care these
patients. In an observational study of patients with COPD diagnosis
conducted by Italian general practitioners, sufficient control of the dis-
ease was reported only in 47.2% of the subjects with over two exacer-
bations in the last 12 months [135]. Suboptimal adherence of GPs prac-
tice to the guidelines for COPD diagnosis and management was shown
in a study conducted in Lombardy region, and confirmed in studies con-
ducted in other regions [135]. These studies highlighted the need to
improve the knowledge of mechanisms of COPD progression among
GPs, promoting the use of spirometry for the diagnostic definition, and
the prescription of pulmonary rehabilitation to symptomatic patients
[136].
Some organizational issues may limit the accessibility to pul-
monary rehabilitation for Italian patients with chronic disabling res-
piratory diseases. Compared to the actual prevalence of COPD pa-
tients in Italy (2.5 to 3 million), in a national study published in 2004,
only 53 rehabilitation departments and/or pulmonology units were es-
timated to warrant availability and accessibility to pulmonary rehabil-
itation, with more than half of them being located in the north of the
country [137]. In some regions, the differences in availability of pul-
monary rehabilitation and integration between acute hospital and
primary care may be related to the higher occurrence of potentially
avoidable hospitalization for COPD [138,139]. Accessibility to pul-
monary rehabilitation may be also hampered by differences among
regional application rules of national health policies across Italy, that
frequently made delivery of pulmonary rehabilitation in unfavourable
competition with rehabilitation of musculoskeletal and neurological
conditions [140].
Different models of integrated care programmes for COPD pa-
tients were developed in recent years, and ongoing projects will un-
doubtedly help determine the feasibility of different components, in-
cluding the application of information and communication technolo-
gies (such as telemedicine) to self-management and pulmonary re-
habilitation [141]. 
Patient education programmes are widely included in pulmonary re-
habilitation programmes, and showed effective in improving patient
knowledge and self-management [142]. A multicentre randomized
controlled trial involving 4 European countries – including Italy – was
recently approved to evaluate effectiveness of a home-based COPD self-
management programme to reduce exacerbations and hospital admis-
sions. The self-management programme will include extensive patient
coaching by healthcare professionals to improve disease management
skills, an e-health platform for reporting health status updates, and
elaboration of a clinical score for early detection of clinical instability
(COMET study) [122].
Home based tele-management of COPD patients in remote areas of
the Lombardy region of Italy has been performed providing home-based
tele-management services for patients with chronic heart failure and
COPD, as well as second-opinion tele-consultations in cardiology, der-
matology, diabetology, and pulmonology for general practitioners
[143]. A recent retrospective study exploring patterns of usage of
home-based tele-management in COPD, showed that “frequent re-
lapsers” are most likely to require scheduled and unscheduled tele-
management services [144]. Additionally, in a recent retrospective
study of chronically hypercapnic COPD patients on long term oxygen
therapy, tele-assistance combined with non invasive ventilation re-
duced the frequency of exacerbations [145]. In contrast, a crossover
randomised controlled trial showed that telemonitoring added to stan-
dard care did not improve either the time to next acute hospitalization,
or health-related quality of life in COPD [146].
An ongoing research project in the Tuscany region of Italy, funded by
the National Health Ministry Research Grant, is currently exploring
cost-effectiveness of the implementation of a system of telecare in
COPD patients with multiple morbidities. This system uses simple,
low-cost tools (symptoms diaries, action plans) and frequent contacts
with health personnel. Preliminary data show an increase of knowledge
level of GPs in COPD guidelines adherence, with high rate of treatment
modification (53%) after enrolment in the integrated care programme
(unpublished data). 
In summary, the optimal care for patients with COPD requires a pa-
tient-centred approach, integrating medical care among healthcare
professionals redesigning hospital and home care pathways. This need
has led to the development of novel approaches in Italy. This is cur-
rently a work in progress. 
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mentary disciplines, with the goal of the patient living and functioning
independent within society [152]. The 2013, the American Thoracic
Society – European Respiratory Society Statement defined pulmonary
rehabilitation as, “… a comprehensive intervention based on thorough
assessment followed by patient-tailored therapies designed to improve
the physical and psychological condition of people with chronic respira-
tory disease and to promote the long-term adherence to health-en-
hancing behaviors” [36]. The latter part of this definition fits with the
definition provided in the addendum in the American Association for
Respiratory Care, which stipulates that pulmonary rehabilitation
should be both restorative and preventive [153].
The major, common points among the various definitions of pul-
monary rehabilitation include: i) a focus on chronic respiratory pa-
tients and their care givers; ii) an individualization of the intervention;
iii) an ongoing multidisciplinary intervention; iv) outcomes based on
physiological, psychological and social measures considering a global
dimension to the individual’s health; and v) the stimulation of long-
term adherence to health-enhancing behaviours in order to promote
autonomy and social participation of the patient. 
The diagnosis of physiopathological and psychopathological problems
in the individual patient forms the start of every pulmonary rehabilita-
tion programme. Such assessment is performed in every referred patient
for pulmonary rehabilitation in the expertise centre, CIRO+. This centre
for integrated rehabilitation for chronic respiratory conditions is located
in the southern part of the Netherlands. CIRO+ is a member of the Dutch
Lung Centers, specialised third-line centres for chronic respiratory care. 
Pulmonary rehabilitation advocates a personalized approach, and
aims for patients with COPD to acquire and apply participatory and pre-
ventive skills to make them, together with healthcare professionals,
more pro-active in the daily management of their disease. This process
of healthcare organization around the patient (i.e., adopting a patient-
centered approach) is generally underestimated or neglected in the
management of patients with chronic conditions as COPD [154].
Ideally, COPD management must offer a flexible, holistic, and inte-
grated intervention, based on partnering of different skills to achieve
shared, individualized, patient-related objectives, with a goal to achieve
improvement in clinically-relevant outcomes and added value to the pa-
tient and the community. This requires a process-based organization to
manage business around these core processes, including intake and as-
sessment, rehabilitative therapies, and outcome evaluation [155].
Socio-technical systems theory has the following characteristics: i)
designing and changing organizations in response to environmental
conditions and strategic choices; ii) addressing the increasing com-
plexity of organizations that results from increasing external uncer-
tainty and variation within the internal division of labour; and iii) of-
fering a tailor-made, individualized programme [156]. Socio-technical
theory offers a framework to improve efficiency, quality, flexibility and
innovation. Indeed, a key feature of socio-technical design involves
bringing together people from different roles and disciplinary back-
grounds who have different skills, experience and expertise. Pluralism
is the norm, and this implies they share their views and expertise. Par-
ticipants from different backgrounds educate one another in the op-
portunities that may exist for the design of a new system, each con-
tributing to the design process [157]. Socio-technical theory offers a
framework for healthcare organizations to create value through im-
proving outcomes that matter most to patients, always taking into con-
sideration the costs of achieving those outcomes [158].
CIRO+ rehabilitation centre is based on this socio-technical systems
theory. Its approach is holistic and organized around the individual and
his/her experienced needs. CIRO+ operates as an integrated practice
unit (IPU) that treats not only a disease but also the related conditions,
complications, and circumstances that commonly occur along with it.
The CIRO+ Program: an integrated, holistic,
personalized medical strategy
Key points
• A thorough patient assessment is mandatory at the beginning
of every rehabilitation program
• Socio-technical systems theory can be very supportive for or-
ganisation of pulmonary rehabilitation
• Outcomes after pulmonary rehabilitation are non-linear, dif-
ferential and multidimensional
• Pulmonary rehabilitation improves health through improving
the patient’s well being
Cardiovascular diseases, cancers, chronic respiratory diseases and di-
abetes are the four major chronic non-communicable diseases (NCDs).
To a great extent, NCDs develop as a result of an unhealthy lifestyle, such
as tobacco use, physical inactivity, unhealthy diet or the excessive use of
alcohol [147]. The risk factors for the major NCDs are still increasing
worldwide. One of the greatest challenges to healthcare management is
to understand the growing complexity of these chronic NCDs. Current
health care ignores this heterogeneity in the burden of NCDs and largely
fails to offer a personalized, patient-centred approach to management. 
It is recognized that COPD is a complex, heterogeneous syndrome
with numerous pulmonary and extra-pulmonary components [148].
The presence and severity of COPD has been traditionally diagnosed by
assessment of the degree of airflow limitation. However, it is nowadays
generally accepted that accurate characterization can not be achieved
by isolated use of measures of airflow limitation such as the FEV1
[148]. Significant heterogeneity exists in clinical presentation, physi-
ology, imaging, response to therapy, decline in lung function, and sur-
vival amongst patients with COPD, irrespective of the degree of airflow
limitation [148]. Furthermore, exacerbations and comorbidities con-
tribute to the overall disease severity in individual patients [149]. 
Recognizing the importance of factors other than airlow limitation,
the Global Strategy for the Diagnosis, Management and Prevention of
COPD (GOLD) has proposed a three-domain assessment of COPD,
which includes the level of symptoms experienced by the patient and
the risk of exacerbations [149]. It is now widely recognized that
grouping of COPD into clinically-meaningful subgroups or phenotypes
is needed to guide more effective therapies and management strate-
gies. A COPD phenotype should be able to classify patients into distinct
subgroups possessing uniform and distinct features, with the aim of fa-
cilitating the assessment of biological mechanisms, prognosis and clin-
ically meaningful outcomes [148]. Furthermore, sub-grouping of pa-
tients may be helpful to identify those who stand to benefit from a par-
ticular treatment, such as pulmonary rehabilitation.
A patient-centred approach of patients with chronic respiratory dis-
eases such as COPD is not new in pulmonary medicine. Indeed, the first
authoritative statement of pulmonary rehabilitation from the American
College of Chest Physicians, published in 1974, introduced pulmonary
rehabilitation already as an “art of medical practice”, wherein an indi-
vidually tailored, multidisciplinary programme was formulated [150].
Through accurate diagnosis, therapy, emotional support and education,
pulmonary rehabilitation stabilizes or reverses both physiopathological
and psychopathological manifestations of pulmonary diseases. Also, it
helps return the patient to the highest possible functional capacity al-
lowed by the handicap and overall life situation [151]. 
In 1994, the National Institutes of Health defined pulmonary reha-
bilitation as a multidimensional continuum of services for the patient
and the family supplied by an integrated team of specialists in comple-
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In an IPU, personnel regularly work together as a team towards the
common goal of maximizing the patient’s overall outcomes as effi-
ciently as possible. Actually, organizing pulmonary rehabilitation ac-
cording to the socio-technical principles as set-up in CIRO+, meets the
features of a high-value healthcare organization [159].
The pulmonary rehabilitation programme has a modular structure,
with basic modules and step-up modules. Decision-making in step-up
modules is based on the outcomes of the assessment procedure. Every
module integrates a spectrum of activities in that particular domain.
This modular approach makes it possible to individualize the interven-
tion. Examples of treatment modules are physical fitness, hydrotherapy,
individual outdoor activity, addressing body composition abnormalities,
addressing co-morbidities, dyspnea management, exacerbation man-
agement, increasing life activity, functional training, adherence
training, partner therapy, and physical fitness.
Based on experience with the CIRO+ programme, it became clear that
responses after pulmonary rehabilitation are differential and multi-di-
mensional among patients. Furthermore, these responses are non-linear,
so and clusters of very good and good responders could be identified. In
that way, pulmonary rehabilitation can importantly downsize the experi-
enced disease burden and can improve physical, emotional and social
functioning of referred patients [160]. Indeed, pulmonary rehabilitation
importantly supports patients to adapt and manage their own wellbeing,
in light of the physical, emotional and social challenges of life [160].
Pulmonary rehabilitation can achieve these improvements in health
status by considering patients as complex adaptive systems where ill-
ness is the result from complex, dynamic and unique interactions be-
tween the different components of the overall system. Because of this,
outcomes are largely unpredictable and highly-dependent on the con-
text in which the program is delivered [161,162], underscoring the
need for all healthcare professionals to partner with the patient and
work closely with other providers to enhance outcomes [154].
To summarize, CIRO+ aims to attenuate the personal and societal
burden of chronic respiratory diseases through developing and imple-
menting personalized, innovative diagnostic, preventive and thera-
peutic solutions and delivery systems.
Medical management of the at-risk COPD patient
For the purposes of this discussion, the at-risk COPD patient is either
hospitalized or recently discharged following an exacerbation of the dis-
ease. The best model for treating the at-risk COPD patient has yet to be
determined. The following is one proposal, based on an integrated care
model for COPD management [88], focused on the high-risk patient, and
enhancing lines of communication to provide a seamless transition of
care from the hospital to the home and on into the community. Elements
include standardizing education based on collaborative self-management,
employing an interdisciplinary team intervention during and in the crit-
ical weeks after a COPD hospitalization and fostering lines of communi-
cation using a novel multi-directional telemonitoring system. This plan of
care is specific to one institutional setting in one health care system, so
– even if it works – its generalizability is open to question.
i) Initial focus on the hospitalized, dual-eligible COPD patient. This
group of patients has markedly impaired health status and very
high risk for subsequent health care utilization and mortality. 
ii) Use of an interdisciplinary, COPD management team approach,
including an advanced practice registered nurse (APRN), pulmo-
nologists, hospitalists, respiratory therapists, pulmonary rehabili-
tation coordinators, a case manager managing telemonitoring,
hospital case managers, hospital educators, a database coordi-
nator, and administrative support staff. All these team members
are currently hospital staff managing COPD as part of their duties.
This team will meet quarterly.
iii) Standardization of COPD educational material for patients. 
iv) Training of the team in self-management principles [163] and
health coaching using motivational interviewing [94].
v) Decision support: standardized management plans for the hospi-
talized COPD patient, with attention to medications and discharge
planning.
vi) Every hospitalized (therefore, at-risk) patient is evaluated within
the first two days by the APRN, and subsequently by selected mem-
bers of the interdisciplinary team, as needed, during the hospital-
ization. The APRN will see the patient throughout the hospital stay
and (along with members of the team) within one week of hospital
discharge. This ongoing interaction beginning early on in the hos-
pitalization and continuing through that hospitalization and into the
post-discharge period will foster the continuity of care that is often
lacking. The APRN will serve as a liaison between the hospitalists,
floor nurses, case managers, and subspecialist physicians. Further-
more, the APRN will also serve as the liaison to the primary care
providers, home care professionals and selected professionals.
vii) Follow-up visit(s) to the team beginning within one week of hospital
discharge. Despite comprehensive written and personalized instruc-
tions at the time of hospital discharge, discharge instructions are
uncommonly followed exactly by patients, leading to pronounced
confusion over medications, inhaler use, and follow-up visits. These
follow-up visits will be used to clarify medication issues and to eval-
uate and treat destabilization of the disease process or worsening of
co-morbid conditions such as heart failure. Patients will be con-
tacted by the coordinator, and provided transportation, if necessary.
viii) Multi-directional telemedicine will be employed, enhancing com-
munication in patient-caregiver, caregiver-patient, and caregiver-
caregiver areas, making it truly multidirectional in scope. All at-
risk patients will be offered telemonitoring; this will be introduced
to the patient at the time of the hospitalization, and implemented
either during the hospitalization or during the first follow-up visit
within one week of hospital discharge. Reinforcement of its use
will be given during the one week hospitalization. 
ix) The patient with dual morbidity – COPD and heart failure – will be
managed using additional input from our hospital’s CHF manage-
ment team and utilizing a novel telemedicine program created to
follow patients with both conditions. 
x) Transitioning care of the COPD patient to the primary care
provider is an integral component of the chronic care model and
of this proposed program. During the initial, post-discharge, crit-
ical period where the interdisciplinary team is playing a major role
in patient management, the primary care provider will have ac-
cess to patient management data through the medical record and
from evaluation notes generated by the team and sent directly to
the provider. The team, by protocol, will notify the provider of the
patient’s recent hospitalization, and provide information on the
assessments and changes in therapy. Following stabilization, the
team will transition care to the health care provider; this will in-
clude updating diagnoses, treatments, special needs, and other in-
terventions and sending this information to the provider. The goal
is to return total management of a stabilized patient back to the
provider. The team, however, will continue to be a resource to the
primary care provider and could intervene again, when necessary. 
xi) Quality improvement will be accomplished through regular, quar-
terly meetings of the COPD management team, and through
monthly meetings of a team analysing reasons for hospital re-ad-
missions in those patients re-admitted within 90 days; the latter sub-
committee will report back to the total COPD management team.
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